Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

OB Nest; Redefining Continuity of Care for Expectant Mothers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02082275
Recruitment Status : Completed
First Posted : March 10, 2014
Last Update Posted : January 8, 2016
Sponsor:
Information provided by (Responsible Party):
Abimbola Famuyide, Mayo Clinic

Brief Summary:
The study defines a new model of prenatal care called OB Nest which will be compared to the traditional model of prenatal care. OB nest is intended to create an experience for patients that feels more connected and patient-centered, allowing the patient to visit the clinic less frequently while offering increased communication with the OB nurses and providers through new tools provided to the patient. The goal of the project is to promote patient-centered care through a new prenatal care program based on constant and direct support from a nursing team, meeting the on-demand needs of expecting mothers as they rise, and as thus, redesigning the need and timing of on-site appointment with providers. Pregnant women randomized to the OB Nest cohort will see the number of pre-planned visits with their providers decreased and replaced with more direct and constant support and interaction with an assigned nursing team.

Condition or disease Intervention/treatment Phase
Pregnancy Other: OB Nest Not Applicable

Detailed Description:

OB Nest is a model designed to promote increased patient-centered care during pregnancy. OB Nest care will allow for more flexibility, decrease interruptions to your productivity, while continuing to maintain safety for you and your infant. This model of care is anticipated to allow you more access to your health care team during your pregnancy.

This study will compare OB Nest, a new model of prenatal care, to the existing traditional model of prenatal care. The plan is to have about 300 low-risk mothers take part in this study. Eligible patients will be randomized to one of two groups; The Traditional Prenatal care Group or the OB Nest Group. Mothers will have an equal chance of being assigned to the OB Nest group. Mothers randomized to the OB Nest intervention will be assigned to a nursing care team comprised of one to three nurses and see their initial eleven planned appointments with their provider reduced to six. Mothers will still be able to request additional in-office visits with their provider and/or the provider require additional in-office visits to monitor mother and infants safety/care.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Implementation and Evaluation of the OB Nest Project at the Point of Care: Redefining Continuity of Care for Expectant Mothers.
Study Start Date : February 2014
Actual Primary Completion Date : October 2015
Actual Study Completion Date : November 2015

Arm Intervention/treatment
Experimental: OB Nest
OB Nest is designed to reduce the number of pre-planned visits with their OB provider and replace the in-clinic visits with a direct and constant support from an assigned nursing team. OB Nest will empower moms-to-be to take ownership of their prenatal care by providing a wealth of resources.
Other: OB Nest
  • Reduction in the number of clinic office visits
  • Assignment to a specific nursing care team
  • Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.
  • Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.
  • Augmentation of in-person visits between care providers and patients with video conversations.
  • Maternal outcomes will be monitored through surveys and questionnaires.

No Intervention: Traditional Prenatal care
Traditional prenatal visits in clinic with OB providers.



Primary Outcome Measures :
  1. Expectant mothers satisfaction of prenatal care [ Time Frame: 36 weeks ]
    At 36 weeks the expectant mother will complete a survey that assessed their satisfaction of the prenatal care received using a validated scale.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18+ years of age
  • Documented gestational age less than 13 weeks.
  • Pregnancy documented as low risk (See high risk exclusion criteria below)
  • Able to read and understand English
  • Able to provide informed consent (i.e. no impairments or barriers)

Exclusion Criteria:

Clinical judgment that determines that the pregnancy is at high risk for complications.

Any of the following high risk factors would disqualify the mother for the study:

  • Severe hypertension (>160/110)
  • Possible ectopic
  • Congenital adrenal hypertension
  • Prior PE/DVT/stroke
  • Anticoagulation during prior pregnancy (e.g. antiphospholipid antibody syndrome)
  • Prosthetic heart valve (non-bio)
  • Pulmonary hypertension
  • Mothers currently taking Immunosuppressants, Prednisone > 10mg per day, antipsychotic (e.g. lithium, Haldol, Zyprexa), chemotherapy
  • Recurrent pregnancy loss (>2 losses)
  • Current maternal malignancy
  • Prior myocardial infarction/cardiomyopathy
  • Bio-prosthetic heart valves
  • Marfan syndrome
  • Active liver disease (e.g. hepatitis)
  • Congenital heart disease
  • Coagulopathies including thrombophilias and bleeding disorders.
  • Pre-existing diabetes
  • Genetic disease/CF testing/anomalies in prior child
  • Incompetent cervix (prior cerclage)
  • Triplets or quads diagnosed by REI or ultrasound.
  • Isoimmunization (Rh, Kell, etc.)
  • History of transplant or currently on Dialysis
  • Recurrent pregnancy loss (antiphospholipid antibody syndrome or collagen vascular disease)
  • Chronic hypertension
  • Prior 2nd or 3rd trimester loss
  • HIV
  • Inflammatory bowel disease
  • Asthma and currently on steroid to control disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02082275


Locations
Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Layout table for investigator information
Principal Investigator: Abimbola Famuyide, MBBS Mayo Clinic
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Abimbola Famuyide, Associate Professor of Obstetrics-Gynecology, Mayo Clinic
ClinicalTrials.gov Identifier: NCT02082275    
Other Study ID Numbers: 13-009513
First Posted: March 10, 2014    Key Record Dates
Last Update Posted: January 8, 2016
Last Verified: January 2016
Keywords provided by Abimbola Famuyide, Mayo Clinic:
Prenatal Care
Obstetrics